<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="23018">Carbonic anhydrase inhibitors</z:chebi> used in the treatment of <z:hpo ids='HP_0000501'>glaucoma</z:hpo> are rarely associated with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood dyscrasias</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Several case reports of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> with use of <z:chebi fb="0" ids="27690">acetazolamide</z:chebi>, and two cases with use of methazolamide, have appeared in the literature </plain></SENT>
<SENT sid="2" pm="."><plain>This report documents two cases of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, at least one of which was almost certainly induced by the use of methazolamide, one case of <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, and two cases of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> related to the use of methazolamide </plain></SENT>
<SENT sid="3" pm="."><plain>In each case several weeks to months elapsed between initiation of therapy and <z:hpo ids='HP_0003674'>onset</z:hpo> of reaction </plain></SENT>
<SENT sid="4" pm="."><plain>This suggests that changes in patients' general medical condition should be continually monitored when using these drugs </plain></SENT>
</text></document>